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(Epi)genomic heterogeneity of pancreatic islet
function and failure in type 2 diabetes
Nathan Lawlor 1, Michael L. Stitzel 1,2,3,*
ABSTRACT
Background: Pancreatic Islets of Langerhans are heterogeneous tissues consisting of multiple endocrine cell types that carry out distinct yet
coordinated roles to regulate blood glucose homeostasis. Islet dysfunction and specifically failure of the beta cells to secrete adequate insulin are
known precursors to type 2 diabetes (T2D) onset. However, the exact genetic, (epi)genomic, and environmental mechanisms that contribute to
islet failure, and ultimately to T2D pathogenesis, require further elucidation.
Scope of review: This review summarizes efforts and advances in dissection of the complex genetic underpinnings of islet function and
resilience in T2D pathogenesis. In this review, we will highlight results of the latest T2D genome-wide association study (GWAS) and discuss how
these data are being combined with clinical measures in patients to uncover putative T2D subtypes and with functional (epi)genomic studies in
islets to understand the genetic programming of islet cell identity, function, and adaptation. Finally, we discuss new and important opportunities to
address major knowledge gaps in our understanding of islet (dys)function in T2D risk and progression.
Major conclusions: Genetic variation exerts clear effects on the islet epigenome, regulatory element usage, and gene expression. Future (epi)
genomic comparative analyses between T2D and normal islets should incorporate genetics to distinguish patient-specific from disease-specific
differences. Incorporating genotype information into future analyses and studies will also enable more precise insights into the molecular genetics
of islet deficiency and failure in T2D risk, and should ultimately contribute to a stratified view of T2D and more precise treatment strategies. Islet
cellular heterogeneity continues to remain a challenge for understanding the associations between islet failure and T2D development. Further
efforts to obtain purified islet cell type populations and determine the specific genetic and environmental effects on each will help address this.
Beyond observation of islets at steady state conditions, more research of islet stress and stimulation responses are needed to understand the
transition of these tissues from a healthy to diseased state. Together, focusing on these objectives will provide more opportunities to prevent,
treat, and manage T2D.
 2019 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. TYPE 2 DIABETES: A DISEASE OF MANY FACES
Like all other forms of diabetes, type 2 diabetes (T2D) is fundamentally
a genetic disease. It is a complex, polygenic disorder with substantial
environmental contributions and multiple geneeenvironment in-
teractions. It manifests when insulin resistance unmasks intrinsic
flaws in islet sensory and/or secretion machinery or impaired resilience
and compensation mechanisms, ultimately leading to beta cell failure
and death and insufficient insulin secretion. In contrast to monogenic
forms of diabetes, which overwhelmingly alter protein-encoding DNA
sequences, genome-wide association studies (GWAS) have revealed
that the large majority of DNA sequence changes linked to T2D reside
in non-coding regions of the genome. Recent studies have highlighted
the genetic variability of T2D through quantitative (epi)genomic and
clinical measures of human islet function. As (epi)genomic editing
technologies such as CRISPR-Cas9 become more widespread in the
field, further studies will be able to perturb specific (epi)genetic
elements in various islet cell line and whole animal models to bridge
the gap between diabetes genetic susceptibility and phenotypes.
Examination of patient clinical measurements of islet function alone
also provide substantial insights into T2D heterogeneity. One study that
performed a topological analysis of 2,551 T2D patients and their
corresponding clinical data identified 3 subtypes of T2D with each
group showing a distinct and strong association with either diabetic
microvascular complications, cardiovascular disease, or neurological
diseases and allergies, respectively [1]. Three years later, Ahlqvist and
colleagues analyzed a cohort of 8,980 Eastern European individuals
with diabetes and subdivided patients into 5 distinct groups with
different disease progression and clinical complications [2]. The first
subgroup of patients (n ¼ 577) was labeled as severe autoimmune
diabetes based on a high prevalence of auto-antibodies for zinc
transporter 8A (ZnT8A). Group two (severe insulin deficient diabetes;
n ¼ 1575) was characterized by poor metabolic control (highest gly-
cated hemoglobin (HbA1c) levels) and insulin deficiency, while
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individuals in group three (severe insulin resistant diabetes; n¼ 1373)
had higher BMI and insulin resistance. The fourth group (mild obesity
related diabetes; n ¼ 1942) possessed the highest average BMI and
individuals in the fifth group (mild age-related diabetes; n¼ 3513) had
the latest average age of disease onset. Notably, individuals from
groups 1 and 2 had an increased prevalence of ketoacidosis at
diagnosis and poor sustained insulin use. Patients in group 2 were also
at a high risk for diabetic retinopathy while group 3 patients had a
higher risk for kidney disease and diabetic complications (e.g., stroke,
etc.). Further collection of patient clinical data and stratification into
different subgroups of T2D can help guide medical professionals to
design more successful and precise medical solutions. Distinct sets of
T2D risk variants were also enriched in each of these clusters, sug-
gesting these may represent genetically distinct T2D subtypes.
2. T2D GENETICS, SUBTYPES, AND MODULES
In late August 2018, the DIAMANTE consortium reported the identification
of 243 T2D risk loci, 135 of which were newly discovered in the latest T2D
GWAS meta-analysis of almost 900,000 individuals (74,124 cases and
824,006 controls) [3]. They identified 403 signals in 243 T2D risk loci, with
approximately two-thirds (n¼ 151) containing one association signal and
the remaining comprising 2e10 distinct ones. Importantly, the approxi-
mately three-fold increase in effective sample size enabled the identifi-
cation of ‘credible’ sets of putative functional SNPs in each locus using
genetic fine-mapping approaches. These efforts reduced the putative
functional variants to less than 50 for over half of the association signals.
For 101 loci, they refined the credible set of SNPs to 10 or fewer variants.
Qualitatively, this study underscored conclusions from previous work by
the T2D-GENES and GOT2D consortia on the potential regulatory nature of
these T2D-associated sequence changes [4], as the large majority of these
credible set SNPs overlap non-coding regions of the genome. Most of the
T2D risk alleles are considered to act at least in part through islets, given
their correlation with quantitative measures of islet function.
Clinically, analysis of T2D genome wide association study (GWAS) data
(consisting of 94 independent T2D variants and 47 diabetes associated
traits) identified five distinct groups of T2D loci [5]. Two of these groups
had variant trait associations related to reduced beta cell function and
insulin deficiency, of which the two differed by their proinsulin levels.
The remaining three groups were characterized by variants associated
with insulin resistance and were subdivided into obesity mediated (via
high body mass index (BMI) and waist circumference (WC)),
lipodystrophy-like fat distribution (low BMI, high cholesterols and tri-
glycerides), and disrupted liver lipid metabolism (low triglycerides).
Interestingly, from 4 independent T2D populations of European
ancestry, they observed that 5,449/17,365 (w30%) of individuals were
classified to a single group based on clinical measures of BMI, WC, C-
peptide, high density lipoprotein (HDL), and triglycerides. These findings
are important because they not only highlight the genetic heterogeneity
of T2D, but also show that these genetic modules are supported by
patient clinical data. Additional, more precise phenotypic measure-
ments, such as intravenous glucose tolerance test (IVGTT)-based
measures of first phase insulin secretion [6], will be critically important
to help the community more precisely parse the relevant tissue(s), cell
type(s), and physiologic process (es) affected by T2D-associated SNPs.
3. FUNCTIONALIZING GENETIC VARIATION OF ISLET FUNCTION
AND FAILURE
Given their non-coding locations in the genome, it seemed plausible
that at least a subset of T2D GWAS SNPs might alter the use or activity
of cis-regulatory elements (REs) controlling islet gene expression.
Multiple groups completed epigenome profiling of islets at the level of
chromatin accessibility, histone post-translational modifications, spe-
cific islet transcription factor binding, and DNA methylation to identify
putative regulatory regions and specific cis-REs [7e13]. Integration of
these epigenomic maps and overlap with T2D GWAS SNP locations
revealed a significant and specific enrichment in active regulatory
regions, most notably in islet-specific stretch enhancer chromatin
states [8] (http://theparkerlab.org/tools/isleteqtl/) or enhancer clusters
[9] (http://www.isletregulome.org/isletregulome/), than would be ex-
pected by chance. Naturally, this led to the hypothesis that GWAS
variants alter islet cis-RE use and expression of their gene targets to
contribute to islet dysfunction and failure.
Key challenges to translating these statistical associations into mo-
lecular, cellular, and phenotypic insights include: 1) identifying the
putative function-altering variant(s) among the tens to hundreds of
genetically linked variants in a given locus; (2) determining the gene or
genes that are the targets of these variants; and (3) elucidating the
effect(s) of these variants on cis-RE use and activity and target gene
expression. Over the past few years, studies have employed a variety
of complementary approaches leveraging new technologies to uncover
fundamental regulatory programs of islet cell identity and function
using human islets and surrogate human and rodent beta cell lines and
understand their genetic programming.
3.1. Identifying putative functional variants
Complementary in vitro and in vivo approaches have been developed
and employed to nominate putative causal variant(s) among a set of
genetically linked SNPs. Traditional reporter assays such as luciferase
have been used as in vitro tools to test putative promoter or enhancer
sequences for regulatory activity and to successfully identify
expression-modulating effects of select candidate T2D GWAS SNPs,
usually at the scale of one to tens of test sequences at the most.
Unfortunately, they are too expensive and time consuming to sys-
tematically assess the hundreds to thousands of T2D credible set SNPs
for their ability to modulate reporter activity. Massively parallel reporter
assays (MPRA) allow one to create pooled libraries of thousands of
DNA sequences and test for their effects on reporter gene expression in
a single transfection. MPRA can be used both to test relative regulatory
element activity of distinct sequences and to assess and compare the
gene regulatory effects of GWAS SNPs (Figure 1). Barcoded reporter
gene (e.g., gfp) transcripts are sequenced and quantified by RNA-
sequencing. To identify sequences possessing cis-RE activity, bar-
code counts in the RNA-sequencing data are compared to those in the
original plasmid library. Moreover, expression-modulating effects of
GWAS SNP effects on cis-RE activity can be identified by comparing
RNA-seq barcode counts of the DNA sequences containing the T2D
risk and non-risk alleles. To date, most MPRA studies have tested the
ability of selected DNA sequences to enhance the transcriptional ac-
tivity of a minimal promoter, but there is potential to apply more so-
phisticated techniques to test combinatorial enhancer-promoter
sequence effects.
Although these assays have not been conducted yet with T2D GWAS/
credible set SNPs, their utility has been demonstrated for the study of
other traits and diseases. For example, Tewhey et al. tested approxi-
mately 30,000 SNPs associated with expression differences in lym-
phoblastoid cell lines (LCLs) [14]. 12% of these sequences significantly
altered reporter activity, with 95% of those exhibiting increased,
enhancer, activity. These sequences overlapped epigenetic hallmarks
of active regulatory elements in LCLs, including active histone tail
modifications (such as H3K27ac), open chromatin sites, and ENCODE
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LCL transcription factor binding sites. As anticipated, these active
sequences were enriched for DNase hypersensitive sites that were
unique to LCLs and not those for other cell types. Together, these data
suggest that MPRA are capable of predicting DNA sequence regulatory
activity relevant to in vivo contexts and warrant their use as a tool to
identify putative functional variants among the hundreds to thousands
of T2D credible set SNPs.
Alternatively, SNP effects on in vivo regulatory element use can be
deciphered from (epi)genomic profiles if the individual from which they
were generated was genotyped. This information can be leveraged in
two ways. If these profiles are generated from multiple genotyped
individuals, chromatin accessibility quantitative trait locus (caQTL)
analysis can be performed to identify SNP alleles that alter chromatin
accessibility (as depicted in Figure 1). Khetan et al. recently completed
ATAC-seq analysis of human islets from 19 donors to identify
approximately 150,000 open chromatin regions (OCRs) genome-wide
[15]. caQTL analyses identified 2949 OCRs whose accessibility was
modulated by the genotype of a SNP residing within it. caQTL were
located in distal (putative enhancer) OCRs at a rate three-fold higher
than proximal (promoter) OCRs (30% vs. 12%). Open chromatin re-
gions containing caQTLs were enriched for sequence motifs and
empiric binding (as determined by ChIP-seq) of FOXA2, PDX1, MAFB,
and NKX6-1. It therefore appears that the chromatin-modulating ef-
fects of these variants may be mediated through differential binding of
islet transcription factors. As might be anticipated based on their
predominantly distal locations and overlap with islet transcription
factor binding sites, these caQTL are fairly islet-specific. For the SNPs
demonstrating significant effects on islet gene expression (eQTL SNPs;
[11,16,17]), directions of the chromatin and gene expression effects
were consistent, i.e., T2D risk alleles closing chromatin were also
linked to decreased gene expression. Importantly, overlap with the
locations of T2D-associated SNPs in the NHGRI/EBI GWAS catalog
nominated putative functional SNPs for 13 T2D-associated loci. This
included rs11708067 in the ADCY5 locus, which also exhibited sig-
nificant allelic imbalance in an independent study [13] and has been
linked to altered ADCY5 expression in human islet eQTL analyses
[11,16,17]. Of note, the T2D risk allele increased chromatin accessi-
bility for seven of these SNPs and decreased it for the other six. These
data suggest that both decreased and increased activity of certain
genes and pathways contribute to islet dysfunction and T2D.
3.2. Identifying target genes
Two complementary approaches can and have been employed to
identify the putative gene targets of islet cis-REs, particularly those
related to central islet functions such as insulin biogenesis or over-
lapping GWAS SNPs. Similar in principle and approach to caQTL an-
alyses, expression quantitative trait locus (eQTL) analyses assess how
genetic variation influences gene expression levels. To date, analyses
of steady state gene expression in two independent cohorts identified
2341 and 616 islet eQTLs, respectively. Among the 216 eQTLs
detected in both cohorts, 14 were linked to T2D-associated SNPs. This
modest overlap between T2D associated SNPs and steady state islet
Figure 1: Assessing the relationship between T2D-associated genetic variation and islet (dys)function. Multiple SNPs (S1eS13) in close proximity that are associated with
T2D occur in a non-coding region of the human genome (denoted as T2D Region #1). Epigenomic profiling identifies distinct regulatory elements (R1-R9) across the genome. In this
example, cis-regulatory element R2 and T2D SNP S3 directly overlap. Chromatin looping analyses identify physical interactions/proximity between regulatory elements to identify
gene targets of given cis-regulatory elements. Individual genetic variation influences chromatin accessibility at this region and also impacts expression levels of interacting genes
(Gene 2). Massively parallel reporter assays (MPRA) provide an in vitro system to determine how each of thousands of T2D-associated SNPs affect transcriptional activity of a
reporter gene. SNPs ¼ single nucleotide polymorphisms; T2D ¼ type 2 diabetes; mP ¼ minimal promoter; GFP ¼ green fluorescent protein; pA ¼ polyadenylation signal.
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eQTL may be due to (1) limited power to detect eQTLs with these
sample sizes; (2) the distinct locations of the majority of detected eQTL
(promoters) compared to GWAS SNPs (enhancers); or the possibility
that many T2D GWAS SNPs modulate physiologic or pathologic islet
responses. eQTL meta-analyses of the gene expression from hundreds
of islets across multiple groups should help resolve these questions.
Techniques that interrogate the 3-dimensional architecture of human
islets and beta cells have revealed important regulatory features and
uncovered extensive enhancereenhancer, enhancer-promoter, and
promoter-promoter links. Initial insights were derived from targeted
approaches such as circular chromatin conformation capture (4C) to
identify regions interacting with promoters of the INS gene [18,19] or
those of other select genes, such as the transcription factors PDX1 and
ISL1 [9]. These targeted approaches revealed extensive intra-
chromosomal looping interactions with multiple putative enhancers,
some at ranges up to hundreds of kilobases to megabases away. When
Xu and colleagues blocked INS promoter activity, both contacts with
and expression of the interacting genes SYT8 and ANO1 decreased
[19]. Interestingly, both of these genes promote insulin secretion,
which led the authors to suggest a model wherein physical association
of genes involved in insulin metabolism with the highly transcribed INS
locus stimulates their expression. Surprisingly, 4C-seq in human
EndoC-bH1 beta cells detected contacts between the INS promoter
and gene loci on multiple other chromosomes, including both type 1
and type 2 diabetes GWAS loci [20]. As the technical vs. biological
nature of trans-chromatin interactions and their meanings is still
debated, it will be exciting to see if the existence or dynamics of in-
teractions between these GWAS loci and INS in these potential tran-
scription factories contribute to the underlying molecular mechanisms
of their association with either type 1 or type 2 diabetes in people.
Nonetheless, these studies of a handful of specific sites reveal sur-
prising intricacies and potential functional importance of transcriptional
regulation in islet cell nuclei.
More broadly, the ‘all-by-all’ Hi-C approach was recently applied to
define the genome-wide location of chromatin interactions and define
chromatin territories/neighborhoods in pancreatic islets from one in-
dividual and EndoC-bH1 [21]. The majority (>90%) of Hi-C loops
detected were shared with other cell types. Moreover, the anchor
points of these shared loops were significantly enriched for CTCF and
CTCFL motifs, which suggests that the large majority of chromatin
neighborhoods are dictated by the relatively limited flexibility in con-
formations to pack the chromatin into each cell type’s nucleus. In
contrast, approximately 10% (n ¼ 1,078) of interactions were unique
to EndoC and islets, such as those in the ZnT8 transporter-encoding
SLC30A8 locus, and were enriched for beta cell-specific transcrip-
tion factor binding site motifs [21].
These large-scale Hi-C chromatin neighborhoods in EndoC-bH1 were
further refined into hundreds of actively transcribed promoter-
promoter, promoter-enhancer, and enhancereenhancer interactions
that were revealed by RNA Polymerase 2 ChIA-PET [21]. RNA Pol2
looping sites were notably enriched for beta-cell transcription factors
and brought into close proximity genes associated with glucose
sensing and insulin secretion. Surprisingly, some loci exhibited an
extensive, highly connected network of chromatin interactions, often
consisting of >5 distinct connections. These included gene loci
encoding transcription factors associated with beta cell identity and
development (e.g., PDX1, ISL1, NKX6-1, MAFB, and miR-375) as well
as glucose sensing and insulin metabolism and secretion (e.g., PCSK1,
RIMBP2, RGS7, and CDC42) [21]. Overlap of T2D-associated GWAS
SNPs with any ChIA-PET interactions was modest, however, sug-
gesting that (1) the sensitivity of Pol2 ChIA-PET technology was
insufficient; (2) Pol2-mediated looping with GWAS SNP-containing cis-
REs differs significantly between primary adult human islets and
EndoC-bH1, which appears to retain some epigenomic signatures of
its fetal pancreas origin looping; and/or (3) the looping effect(s) of some
GWAS SNP-containing cis-REs may be condition-specific, as has been
shown in other cell types [22,23]. Additionally, EndoC-bH1 genotypes
may not have permitted assessment of certain GWAS SNPs impacts on
cis-RE usage as only 20e30% of associated loci were heterozygous in
the cell line. The large majority of disease variants were homozygous in
EndoC-bH1 for the non-risk allele. Thus, if the risk allele creates or
activates a cis-RE, it will not be detected in this particular individual.
Nonetheless, these analyses nominated T2D-associated SNPs map-
ping to target genes CEP41 and C11orf54 with consistent alterations
on cis-RE activity and gene expression in islets and EndoC-bH1 [21].
Several studies have demonstrated that the physiology of EndoC-bH1
cells, including insulin secretion and response to glucose, closely
resembled that of islets [24,25]. However, these cells are not
responsive to cytokines [26] suggesting there are significant differ-
ences in some of their functional properties. Further studies of specific
pathways and processes should therefore exercise caution when
extending results found in EndoC-bH1 into primary human beta cells.
Integration of islet and corresponding cell line multi-genomic datasets
with genome-wide genetic variation information, and designing tools to
make this information accessible in an interactive, searchable format
such as in a web application (https://shinyapps.jax.org/endoc-islet-
multi-omics/), will be crucial for nominating further T2D gene targets.
4. PRECISE CELLULAR GENOMICS
Elucidating the molecular mechanisms that lead to beta cell
dysfunction and T2D pathogenesis has been a major focus of diabetes
research for decades. However, advances in single cell genomic
profiling techniques have led to greater understanding of non-beta cell
type transcriptional regulation and suggest that they may play
important roles in hallmark features of beta cell insufficiency and
failure linked to T2D genetic risk and pathophysiology. Single cell
transcriptome analysis of human islet cells indicate that multiple
monogenic diabetes genes are highly expressed in beta cells (e.g.,
PDX1, PAX4, INS, HNF1A, and GCK) [27]. However, other non-beta cell
types express genes mutated in monogenic diabetes (such as PAX6
and RFX6), congenital hyperinsulinemia (HADH, UCP2) and those
implicated as T2D GWAS target/effector genes [28].
Recent study of type 1 diabetic (T1D) human islets has provided
surprising insights into alpha cell biology. In T1D islets, the alpha cell
proportions remain relatively unchanged despite abnormal glucagon
secretion [29]. This dysregulated glucagon secretion is instead
accompanied by decreased expression of important islet transcription
factors including ARX, MAFB, and RFX6 and increased expression of
stress response factors such as ATF4, ERN1, and HSPA5 [29] sug-
gesting that changes in alpha cell identity may ultimately lead to their
dysfunction. Analysis of normal and T2D islet single cells with
simultaneous RNA-seq and patch clamping (patch-seq) also revealed
subpopulations of alpha cells with varying enrichment for ER stress
response genes (e.g., DDIT3, XBP1, PPP1R15A) [30]. Interestingly, this
transcriptomic heterogeneity was consistent in normal and T2D islets
and associated with variability in alpha cell electrophysiological
measures; ER stressed alpha cells had lower cellular size and Naþ
peak current. Prior single cell transcriptomic analyses have also noted
subpopulations of ER-stressed beta cells [31,32] which implicates the
dysfunction of both alpha and beta cells in diabetes pathogenesis.
Similarly, the integrity of beta and alpha cell functions seem to be
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dependent on each other, as under hypoglycemic conditions, T2D is-
lets show reduced insulin, C-peptide, and glucagon secretion [33].
Additionally, during a glycemic clamp experiment, an increase in
glucagon secretion was positively correlated with beta cell function
suggesting that signaling between the two islet cell types is crucial for
maintaining glucose homeostasis.
Studies of delta cells in Sst-Cre transgenic mouse models [34e36]
reveal that timely regulation of insulin secretion is controlled by
various delta-cell specific pathways. Induction of the ghrelin receptor
(Ghsr) in delta cells was correlated with enhanced somatostatin
release and ultimately reduced insulin and glucagon secretion [35,36].
Furthermore, the peptide hormone Ucn3 was shown to be co-released
with insulin from beta cells to activate type 2 corticotropin-releasing
hormone receptor (Crhr2) on delta cells in an alternate pathway that
promotes somatostatin release and negatively regulates insulin levels
[34]. Delta cells are also notably enriched for G protein-coupled re-
ceptors (e.g., GLP1R, GIPR, GPR120) which exert careful control over
metabolism [37]. These receptors are also common therapeutic targets
of T2D, suggesting that treatment and management of the disease
should not neglect delta cell (dys)function and/or survival.
Efforts to characterize the epigenomes of each islet cell type are
emerging and revealing new insights of cellular fate and differentiation.
Two groups have performed open chromatin profiling of purified beta
and alpha cell fractions [10,12] and identified between 1850 and 3999
beta and 5316-27,000 alpha-specific peaks. These cell-specific re-
gions were enriched for transcription factor motifs implicated in cell
development and were enriched for diabetes-associated SNPs. Arda
and colleagues also suggest that the beta cell epigenome is plastic and
capable of being derived from other endocrine and exocrine precursor
cells. Discrepancies in the numbers of cell-specific peaks determined
by both groups are likely due to the cell surface markers used to enrich
for each. CD26/DPP4, used by Arda et al., is a strong positive selector
for alpha cells, which then enables negative selection for beta and
other minor cell populations. However, this method of enrichment for
beta cells will not remove contaminating delta and PP/gamma cells.
Continued development of new tools and markers for islet cell
enrichment, such as NTPDase3 [38] should continue to help us to
understand changes elicited by genetic and environmental factors in
each distinct cell type.
Iterative proteomic screens in human islets are also proving useful for
identifying putative cell-specific surface markers for isolation [39],
wherein beta and delta cell populations were obtained by co-enrichment
for CD9 and CD56. Challenges currently remain to exclusively enrich for
the minor islet cell types (delta, gamma/PP), thus strategies that
negatively select for these cells may be needed. Study of the rarer
gamma/PP cells, which constitute roughly <1e5% of the total islet
volume, remain limited due to the lack of known cell-surface markers for
enrichment and purification (Figure 2). Whole islet analyses are unable to
capture cell type-specific changes and therefore preclude analysis of
their potential roles in T2D genetics and pathophysiology. Given the clear
and extensive genotype effects on cis-RE usage [13,15] and gene
expression [11,16,17] in islets, more extensive analysis of sorted cell
types from multiple individuals is warranted to define a representative
set of islet cell-specific REs and distinguish condition-specific from
genotype-driven effects on their use and activity.
5. ISLET RESPONSES; MOVING BEYOND STEADY STATE
MEASUREMENTS
To date, the overwhelming majority of studies including and assessing
genetic variation have profiled the steady state patterns of epigenetic
modifications and gene expression in islets or their constituent cell
types. Others have compared how these steady state measures differ
between T2D and non-diabetic (ND) individuals [13,16,40e44]. Sur-
prisingly, these studies, especially transcriptome analyses, have
identified only modest alterations despite clear phenotypic differences
in HbA1c and other metabolic traits in T2D vs. ND donors. This sug-
gests that alterations in transcriptional regulation may not contribute to
T2D pathogenesis, or that these (epi)genomic comparative studies are
not effectively capturing the alterations associated with islet (patho)
physiologic decline or T2D onset. Genomic assays such as RNA-seq
provide only a snapshot of tissues’ or cell types’ transcriptomes at a
given point in time. Genes that are important for islet function and
resilience (e.g., Gene A) and genes whose expression induces islet
failure (e.g., Gene C) would be detected in a comparative analysis
between islets at healthy and T2D states (Figure 3). In contrast, genes
that are temporarily induced by the initiation of islet stress or in the
compensation or pre-diabetic stages (e.g., Gene B) before decline
towards disease state would be missed.
Furthermore, T2D is a complex disease with dynamic ranges of
severity and secondary health complications across individuals. Thus,
comparing single snapshots of gene expression in T2D individuals at
different stages of islet health and disease progression may simply
lead to obfuscation. Longitudinal studies of in vivo epigenetic and gene
expression changes in islets of severe, early onset (db/db) or polygenic,
late-onset (Tallyho, NZO) [45e47] diabetic mouse models may be the
only practical solution to identify the temporal nature of these changes
and identify the molecular features of islet dysfunction, compensation,
and failure in T2D pathogenesis. Indeed, longitudinal analyses of aging
islets in mice identified DNA methylation changes in key genomic
regions associated with beta cell proliferation and metabolism [48].
These findings suggest that changes in the islet (epi)genome and
transcriptome may also be dynamic during the course of T2D devel-
opment and progression.
Alternatively, in vitro, it may be possible to subject human islets to
diabetic-like conditions through the use of inflammatory cytokines and/
or oxidative and ER stress. Already, studies from a few groups have
demonstrated clear differences in islet gene expression, including the
modulation of putative T2D target genes, during stimulatory or stress
responses, and certain epigenetic and gene expression features in
islets are only revealed upon these in vitro or in vivo exposures, such as
glucose-stimulated insulin secretion, palmitate, inflammatory cyto-
kines or other response defects [49e53]. Examining the tran-
scriptomic and (epi)genomic changes of human islets under these
various stressors over time may provide greater knowledge of the
epigenetic and gene expression changes preceding islet stress, failure,
and ultimately diabetes onset.
6. FROM CORRELATION TO CAUSATION: MODELING T2D
VARIANT EFFECTS AND TARGET GENE FUNCTION
Together, the studies highlighted above combine to unveil important
information necessary to translate T2D GWAS statistical associations
into biological knowledge of the genes and mechanisms underlying
T2D risk and progression: the putative functional variant(s), the gene or
genes they regulate, whether the T2D risk alleles activate or inactivate
their targets, and the cell types in which they elicit these effects. The
final, and most critical, step is to take these data, generate testable
hypotheses, and create accurate, or perhaps more importantly, rele-
vant models to determine the molecular, cellular, and physiologic
functions of the T2D-associated target genes and thereby close the
association-biology gap.
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A variety of cellular and animal models have been developed and applied
over the past few years to experimentally manipulate cis-regulatory
elements and their target gene function as it related to beta cell/islet
function, glucose homeostasis, and T2D pathogenesis. CRISPR/Cas9 has
revolutionized our ability to modify genomes and epigenomes almost at
will. Unsurprisingly, CRISPR (epi)genome editing tools can and have
been used to target putative T2D target genes [54] or cis-REs [55] in beta
cell lines and assess their functions. As some of the T2D risk variants
have been linked to increased cis-RE activity and target gene expression,
such as the C2CD4A/B locus [56], the CRISPR activation systems,
comprising a catalytically dead Cas9 (dCas9) protein linked to epigenetic
activator proteins such as the histone acetyltransferases p300/CBP [57]
or synthetic activation module (SAM) [54], will be essential tools to model
the molecular and cellular effects of the T2D risk variant.
Experimental modeling of select T2D-associated islet ‘enhancero-
pathies’ have both yielded success and presented challenges. The
Figure 2: Moving towards a more precise understanding of islet cellular genomics and responses. Proper elucidation of islet (dys)function and its association with T2D
pathogenesis is confounded by individual genetic variation as well as islet cellular heterogeneity. To obtain a better understanding of both, future studies must prioritize strategies
to obtain purified islet cell type populations (e.g., beta, alpha, delta, gamma/PP) via sorting with specific cell surface markers. Characterization of each cell type-specific genomic
profile at baseline, stimulated, and diseased conditions will provide clearer understanding of key cellular and molecular processes that are altered and important in T2D
development. Additionally, by sampling islets from multiple individuals and leveraging genotypes, it will be possible to identify cis-regulatory elements and genes that are
influenced by genetics rather than disease state. SNP ¼ single nucleotide polymorphism; QTL ¼ quantitative trait locus; ER ¼ endoplasmic reticulum.
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ADCY5 locus provides an example of how the complementary ap-
proaches described above can converge to translate the T2D risk
variant statistical associations into consistent phenotypes and
increased biological knowledge. Among several putative functional
SNPs in this T2D-associated locus, one (rs11708067) overlaps an islet
enhancer and alters islet chromatin accessibility [13,15]. The T2D risk
allele reduces chromatin accessibility [13,15] and is linked to reduced
islet ADCY5 expression [11,17,55,58]. Cross-species mapping of
functional regulatory elements identified an equivalent, sequence-
conserved and functional cis-RE in the rat INS-1 (832/13) beta cell
line, and both Adcy5 expression and insulin content were substantially
reduced in INS-1 (832/13) clones in which this cis-RE was deleted
using CRISPR/Cas9 compared to wildtype clones [55]. Finally, ADCY5
silencing in human islets impaired glucose signaling and glucose-
stimulated insulin secretion.
Other loci, such as TCF7L2, illustrate a challenge of studying
‘enhanceropathies’. The genetic and molecular pathophysiology seems
more complicated, with potentially pleiotropic effects. The rs7903146
T2D-associated SNP overlaps an islet open chromatin region (OCR) and
the risk ‘T’ allele is associated with increased TCF7L2 expression and
decreased insulin content and secretion in human islets [59]. However,
TCF7L2 is expressed in multiple metabolically active tissues, and
tissue-specific deletions implicate distinct roles for Tcf7l2 function in
liver and in both pancreatic islet alpha and beta cells to maintain
glucose homeostasis. Some of these complications likely reflect the
differing functional impacts of mutations in the regulatory element vs.
the protein-coding gene. SHH provides an extreme but informative
example of this [60]. SHH is used iteratively during development for
fundamental patterning decisions in different tissues, and Shh whole
body knockouts are embryonic lethal. However, homozygous deletion
of a distal limb enhancer sequence >1 million nucleotides away from
the Shh promoter produces mice with no limbs, and single nucleotide
changes in the equivalent SHH distal limb enhancer in humans cause
polydactyly. We anticipate that direct modeling of the ‘enhancero-
pathies’ by (1) explicitly removing the cis-RE or switching SNP alleles
within it using genome editing or (2) epigenetically modulating its
activity will help to resolve the pleiotropic and contradictory effects of
certain GWAS loci, such as TCF7L2.
7. CONCLUSIONS AND FUTURE PERSPECTIVES
Stratification of genetic risk and progression in T2D and precise un-
derstanding of the molecular, cellular, and physiologic effects of T2D
risk variants are key objectives moving forward. Studies to date have
provided important insights into and surprises about fundamental
features of islet gene regulatory programs and the genetics of T2D. The
extensive effect of genetic variation on islet cis-RE use and gene
expression that has been uncovered, even under steady state, em-
phasizes the importance of sampling multiple individuals for a given
process that is to be studied and of evaluating and incorporating ge-
netic variation into future human islet studies to identify representative,
not ‘reference’, islet responses to stimuli and diabetogenic stressors.
Genetic and environmental factors appear to be impinging on the same
territory of the genome to elicit their (potentially deleterious) epigenetic
effects on islet cell identity and function, namely distal enhancer el-
ements. Incorporation of genotype information for each human islet
sample will allow us to decode the genetic programming of islet
environmental responses and identify T2D SNPs that enhance or
suppress these responses. Together with improving techniques to
purify and obtain distinct islet cell populations, we can better
Figure 3: Challenges with identifying gene expression alterations in type 2 diabetes. Gene expression measurements from RNA-seq data typically represent only a snapshot
of tissues’ or cell types’ transcriptome at a given point in time. In recent comparative analyses of islet intact and single cell transcriptomes from T2D and ND individuals, relatively
few genes are significantly altered despite the clear phenotypic differences between them. This may suggest that the mechanisms that precede islet failure and T2D pathogenesis
are post-transcriptional and cannot be detected in conventional RNA-seq analyses. However, it is also possible that the putative paths of these genes’ alterations over the course of
islet physiological decline and T2D development are simply being missed. Genes that are important for islet function and resilience (e.g., Gene A) and those whose expression
directly induces or is the consequence of islet failure (e.g., Gene C) may be detected in a comparative analysis between islets at healthy and decompensated states. However,
response genes that are temporarily induced by islet stress (e.g., Gene B) would not be detected in this comparison.
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understand each cell type’s genomic architecture and better charac-
terize their roles in islet resilience and failure. Experimental manipu-
lation of the regulatory elements and/or the target genes identified by
(epi)genomic approaches described above and modeling the putative
pathways and processes they implicate in human islet cell lines (e.g.,
EndoC-bH1-H3) is essential to progress from correlation to causation.
Similarly, transitioning from “the” mouse (C57BL/6) to multiple mouse
models for insights into the effects of naturally occurring genetic
variation on islet function and physiology [61] and for manipulation of
key genomic elements should also help characterize the dynamic
range of islet behavior and response.
T2D is a heterogeneous, complex, and progressive disorder, as mul-
tiple subtypes have been identified and associated with different ge-
netic risk and clinical outcome profiles. Future islet genomics studies
that focus on identifying the distinct subgroups of individuals with
distinct genes/pathways that are disrupted and/or contributing to islet
(dys)function at basal and/or responsive states are needed. Further-
more, priority should be given to profiling more islets from pre-diabetic
and T2D individuals to characterize the transition between basal to
stressed to T2D state and determine if there are intermediate signa-
tures for islet failure and T2D onset. Together, this multi-pronged
approach toward studying T2D genetics and islet pathophysiology
will help identify additional targets and opportunities for intervention
that can be exploited for more precise and effective preventative,
treatment, and management options for T2D.
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